IP Library Granted Patent US 9,695,159
Granted Patent B2
US 9,695,159 · App. 15/313,243 · Granted Jul 4, 2017

Process for preparation of canagliflozin

Inventors: Shekhar Bhaskar Bhirud (Mumbai, IN); Samir Naik (Thane, IN); Sachin Srivastava (N. Mumbai, IN); Dinesh Deore (Thane, IN); Sukumar Sinha (N. Mumbai, IN)
Assignee: GLENMARK PHARMACEUTICALS LIMITED
C07D409/10C07D333/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,695,159
App. No.
15/313,243
Granted
Jul 4, 2017
Kind
B2
Abstract

The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.

Claims (25)

1. A compound selected from the following:

2. A process for the preparation of canagliflozin, a compound of formula I, comprising:

a) reacting a compound of formula II with a reducing agent

to obtain a compound of formula III;

b) coupling the compound of formula III with a compound of formula IV

to obtain a compound of formula V;

c) converting the compound of formula V to a compound of formula VI; and

d) converting the compound of formula VI to the compound of formula I.

3. The process as claimed in claim 2 , wherein in step (a) the reducing agent is selected from the group consisting of diborane, diazene, sodium borohydride potassium borohydride, lithium aluminium hydride and diisobutyl aluminium hydride and aluminum hydride.

4. The process as claimed in claim 2 , wherein in step (a) the compound of formula II is reduced to the compound of formula III in the absence of a Lewis acid.

5. The process as claimed in claim 2 , wherein in step (b) the coupling reaction is carried out in presence of a has selected from the group consisting of n-butyl lithium, sec-butyl lithium, sodium hydride, potassium hydride and a isopropylmagnesium chloride.lithium chloride complex.

6. The process as claimed in claim 2 , wherein in step (c) the compound of formula V is converted to the compound of formula VI in the presence of an acid.

7. The process as claimed in claim 2 , wherein in step (d) the compound of formula VI is converted to the compound of formula I by treating the compound of formula VI with a reducing agent.

8. The process as claimed in claim 7 , wherein the reducing agent is triethyl silane.

9. A method of producing canagliflozin, a compound of formula I,

by a process comprising any of the following steps:

a) converting a compound of formula IX to a compound of formula II;

or

b) reacting a compound of formula II with a reducing agent to obtain a compound of formula III;

or

c) coupling a compound of formula III with a compound of formula IV to obtain a compound of formula V;

or

d) converting a compound of formula V to a compound of formula VI;

or

e) converting a compound of formula VI to the compound of formula I.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2016
From: BHIRUD, SHEKHAR BHASKAR; NAIK, SAMIR; SRIVASTAVA, SACHIN; DEORE, DINESH; SINHA, SUKUMAR
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 040460/0268 →
Priority Claims (1)
IN 1766/MUM/2014 · May 27, 2014 · national
Continuity (1)
Related Publication 20170114051A1 · Apr 27, 2017